CNTB News and Press, Connect Biopharma Holdings Limited

2026-03-03 09:35:51 ET More on Short interest: Hims & Hers short interest climbs amid legal risk related to weight loss pill... Michael Saylor’s Strategy tops U.S. short list, but high short interest may not signal...

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory d...

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory di...

– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve a...

2025-12-01 09:06:38 ET Thomas Flaten from Lake Street issued a price target of $9.00 for CNTB on 2025-12-01 13:40:16. The adjusted price target was set to $9.00. At the time of the announcement, CNTB was trading at $2.86. The overall price target consensus is at $1.50 wi...

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory di...

A look at the top 10 most actives in the United States UTime Limited (WTO) rose 19.5% to $0.0239 on volume of 1,443,045,697 shares Aspire Biopharma Holdings Inc. (ASBP) rose 1.0% to $0.1063 on volume of 546,877,189 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.8% to $3.86...

2025-11-12 10:40:39 ET More on Connect Biopharma Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript Seeking Alpha’s Quant Rating on Connect Biopharma ...

– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Comp...

2025-11-03 21:36:24 ET Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST... Read the full article on Seeking Alpha For further details see: Conne...